MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- IPCA LABS - AUROBINDO PHARMA
IPCA LABS vs AUROBINDO PHARMA - Comparison Results
IPCA LABS Change
Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More
AUROBINDO PHARMA 
Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More
Current Valuations
| IPCA LABS | AUROBINDO PHARMA | IPCA LABS/ AUROBINDO PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 22.4 | 9.9 | 227.3% | View Chart |
| P/BV | x | 4.3 | 1.8 | 235.6% | View Chart |
| Dividend Yield | % | 0.3 | 0.6 | 48.9% |
Financials
 IPCA LABS  AUROBINDO PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| IPCA LABS Mar-19 |
AUROBINDO PHARMA Mar-19 |
IPCA LABS/ AUROBINDO PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,042 | 830 | 125.5% | |
| Low | Rs | 590 | 527 | 112.0% | |
| Sales per share (Unadj.) | Rs | 298.6 | 333.9 | 89.4% | |
| Earnings per share (Unadj.) | Rs | 35.0 | 40.4 | 86.7% | |
| Cash flow per share (Unadj.) | Rs | 49.4 | 51.8 | 95.5% | |
| Dividends per share (Unadj.) | Rs | 3.00 | 2.50 | 120.0% | |
| Dividend yield (eoy) | % | 0.4 | 0.4 | 99.8% | |
| Book value per share (Unadj.) | Rs | 247.1 | 237.1 | 104.2% | |
| Shares outstanding (eoy) | m | 126.35 | 585.91 | 21.6% | |
| Bonus/Rights/Conversions | ESOS | ESOP | - | ||
| Price / Sales ratio | x | 2.7 | 2.0 | 134.5% | |
| Avg P/E ratio | x | 23.3 | 16.8 | 138.7% | |
| P/CF ratio (eoy) | x | 16.5 | 13.1 | 125.9% | |
| Price / Book Value ratio | x | 3.3 | 2.9 | 115.4% | |
| Dividend payout | % | 8.6 | 6.2 | 138.4% | |
| Avg Mkt Cap | Rs m | 103,108 | 397,569 | 25.9% | |
| No. of employees | `000 | 13.4 | 17.9 | 75.3% | |
| Total wages/salary | Rs m | 7,874 | 25,849 | 30.5% | |
| Avg. sales/employee | Rs Th | 2,807.0 | 10,956.9 | 25.6% | |
| Avg. wages/employee | Rs Th | 585.8 | 1,447.7 | 40.5% | |
| Avg. net profit/employee | Rs Th | 329.0 | 1,324.3 | 24.8% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 37,732 | 195,636 | 19.3% | |
| Other income | Rs m | 577 | 1,553 | 37.1% | |
| Total revenues | Rs m | 38,309 | 197,189 | 19.4% | |
| Gross profit | Rs m | 6,901 | 39,519 | 17.5% | |
| Depreciation | Rs m | 1,824 | 6,680 | 27.3% | |
| Interest | Rs m | 189 | 2,626 | 7.2% | |
| Profit before tax | Rs m | 5,465 | 31,767 | 17.2% | |
| Minority Interest | Rs m | 0 | 27 | 0.0% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | -881 | 0.0% | |
| Tax | Rs m | 1,042 | 7,269 | 14.3% | |
| Profit after tax | Rs m | 4,422 | 23,645 | 18.7% | |
| Gross profit margin | % | 18.3 | 20.2 | 90.5% | |
| Effective tax rate | % | 19.1 | 22.9 | 83.4% | |
| Net profit margin | % | 11.7 | 12.1 | 97.0% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 23,778 | 153,645 | 15.5% | |
| Current liabilities | Rs m | 10,975 | 120,429 | 9.1% | |
| Net working cap to sales | % | 33.9 | 17.0 | 199.8% | |
| Current ratio | x | 2.2 | 1.3 | 169.8% | |
| Inventory Days | Days | 104 | 135 | 76.7% | |
| Debtors Days | Days | 66 | 64 | 103.5% | |
| Net fixed assets | Rs m | 20,368 | 103,909 | 19.6% | |
| Share capital | Rs m | 253 | 586 | 43.1% | |
| "Free" reserves | Rs m | 30,971 | 138,322 | 22.4% | |
| Net worth | Rs m | 31,224 | 138,908 | 22.5% | |
| Long term debt | Rs m | 1,409 | 1,800 | 78.3% | |
| Total assets | Rs m | 45,507 | 264,544 | 17.2% | |
| Interest coverage | x | 30.0 | 13.1 | 228.7% | |
| Debt to equity ratio | x | 0 | 0 | 348.2% | |
| Sales to assets ratio | x | 0.8 | 0.7 | 112.1% | |
| Return on assets | % | 10.1 | 9.9 | 102.0% | |
| Return on equity | % | 14.2 | 17.0 | 83.2% | |
| Return on capital | % | 17.3 | 23.8 | 72.7% | |
| Exports to sales | % | 45.9 | 0 | - | |
| Imports to sales | % | 16.6 | 0 | - | |
| Exports (fob) | Rs m | 17,308 | NA | - | |
| Imports (cif) | Rs m | 6,266 | NA | - | |
| Fx inflow | Rs m | 17,308 | 97,316 | 17.8% | |
| Fx outflow | Rs m | 6,266 | 40,589 | 15.4% | |
| Net fx | Rs m | 11,042 | 56,727 | 19.5% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 4,923 | 16,220 | 30.3% | |
| From Investments | Rs m | -1,563 | -28,768 | 5.4% | |
| From Financial Activity | Rs m | -1,832 | 19,191 | -9.5% | |
| Net Cashflow | Rs m | 1,528 | 6,656 | 23.0% | |
Share Holding
| Indian Promoters | % | 45.9 | 54.1 | 84.8% | |
| Foreign collaborators | % | 0.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 11.4 | 8.0 | 143.4% | |
| FIIs | % | 25.3 | 27.7 | 91.3% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 17.4 | 10.2 | 170.6% | |
| Shareholders | 36,892 | 69,601 | 53.0% | ||
| Pledged promoter(s) holding | % | 2.1 | 8.6 | 25.0% |
Compare IPCA LABS With: PIRAMAL ENTERPRISES GSK PHARMA DR. DATSONS LABS DR. REDDYS LAB NOVARTIS
Compare IPCA LABS With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends 248 Points Lower; Power and IT Stocks Witness Selling(Closing)
Indian share markets fell sharply during closing hours today and ended deep in the red. The BSE Sensex stood lower by 248 points, while the NSE Nifty closed down by 81 points.
Related Views on News
AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)
Nov 15, 2019 | Updated on Nov 15, 2019For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)
Nov 12, 2019 | Updated on Nov 12, 2019For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Nov 6, 2019 | Updated on Nov 6, 2019Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.
IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)
Aug 27, 2019 | Updated on Aug 27, 2019For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)
Aug 8, 2019 | Updated on Aug 8, 2019For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
More Views on NewsMost Popular
Could this Smallcap Be the Next Page Industries?(Profit Hunter)
Nov 27, 2019A single stock - Coca Cola, made Buffett billions. Here's your chance to break into the crorepati club with a single smallcap stock investment.
A Simple, 7-Step Checklist for Your Trading Success
Dec 4, 2019What we can learn from one of the greatest traders to have ever lived.
Growth Stocks or Value Stocks... What Will Make You More Money in this Bull Market?(Profit Hunter)
Nov 28, 2019Should you invest in growth stocks or value stocks to make strong returns in this market?
The Best Trading Strategy for Fast Profits
Nov 29, 2019Vijay and I have decided to team up and bring you a unique offering never seen before in the Indian stock markets.
This PSU Turned into a Rare 100 Bagger. Others May Follow.(The 5 Minute Wrapup)
Nov 27, 2019The lowest hanging fruit for government to raise capital would be to sell off stakes in non-critical PSUs.
MoreIPCA LABS SHARE PRICE
Dec 10, 2019 (Close)
TRACK IPCA LABS
- Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON IPCA LABS
IPCA LABS 8-QTR ANALYSIS
COMPARE IPCA LABS WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.